免疫与靶向治疗联用:子宫内膜癌治疗新视角

Combination of Immunity and Targeted Therapy:A New Perspective on the Treatment of Endometrial Carcinoma

子宫内膜癌(endometrial carcinoma)作为女性生殖系统三大恶性肿瘤之一,近年来发病率在世界范围内呈上升趋势。复发或转移性子宫内膜癌的预后较差,一线治疗包括铂类药物化疗或激素治疗,目前尚无标准的后续疗法。近年来,人们对子宫内膜癌分子生物学基础的认识有了很大进展,并找到了治疗子宫内膜癌的潜在靶点。靶向治疗如多腺苷二磷酸核糖聚合酶[poly(ADP-ribose)polymerase,PARP]抑制剂和免疫治疗如程序性死亡蛋白-1(programmed death-1,PD-1)及程序性死亡蛋白配体-1(programmed death ligand-1,PD-L1)抑制剂有可能有效对抗特定亚型的子宫内膜癌。临床研究表明,联合使用这些药物可能产生协同效应。现就PD-1/PD-L1抑制剂与PARP抑制剂单一或联合治疗子宫内膜癌的临床研究进展作一综述。

As one of the three major malignant tumors of female reproductive system,the incidence of endometrial carcinoma is increasing all over the world in recent years.The prognosis of recurrent or metastatic endometrial carcinoma is poor.First-line treatment includes platinum chemotherapy or hormone therapy.There is no standard follow-up therapy at present.In recent years,significant advances have been made in the understanding of the molecular basis of endometrial carcinoma,and potential targets for therapeutic endometrial carcinoma have been identified.Targeted therapy such as PARP inhibitors and immunotherapy such as PD-1/PD-L1 inhibitors may be effective against specific subtypes of endometrial cancer.Clinical studies have shown that the combined use of these drugs may have a synergistic effect.This article reviews the clinical research progress of PD-1/PD-L1 inhibitors and PARP inhibitors in the treatment of endometrial carcinoma.